Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model
Fuyuan Wang, Jingjing Meng, Li Zhang, Timothy Johnson, Chi Chen, Sabita Roy, Fuyuan Wang, Jingjing Meng, Li Zhang, Timothy Johnson, Chi Chen, Sabita Roy
Abstract
Opioid analgesics are frequently prescribed in the United States and worldwide. However, serious comorbidities, such as dependence, tolerance, immunosuppression and gastrointestinal disorders limit their long-term use. In the current study, a morphine-murine model was used to investigate the role of the gut microbiome and metabolome as a potential mechanism contributing to the negative consequences associated with opioid use. Results reveal a significant shift in the gut microbiome and metabolome within one day following morphine treatment compared to that observed after placebo. Morphine-induced gut microbial dysbiosis exhibited distinct characteristic signatures, including significant increase in communities associated with pathogenic function, decrease in communities associated with stress tolerance and significant impairment in bile acids and morphine-3-glucuronide/morphine biotransformation in the gut. Moreover, expansion of Enterococcus faecalis was strongly correlated with gut dysbiosis following morphine treatment, and alterations in deoxycholic acid (DCA) and phosphatidylethanolamines (PEs) were associated with opioid-induced metabolomic changes. Collectively, these results indicate that morphine induced distinct alterations in the gut microbiome and metabolome, contributing to negative consequences associated with opioid use. Therapeutics directed at maintaining microbiome homeostasis during opioid use may reduce the comorbidities associated with opioid use for pain management.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
- Docherty MJ, Jones RCW, Wallace MS. Managing pain in inflammatory bowel disease. Gastroenterol. Hepatol. (N. Y). 2011;7:592–601.
- Hilburger ME, et al. Morphine induces sepsis in mice. J. Infect. Dis. 1997;176:183–8. doi: 10.1086/514021.
- Gomes T, et al. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med. 2011;5:e13–22.
- Leppert W. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Drug Des. Devel. Ther. 2015;9:2215–2231. doi: 10.2147/DDDT.S32684.
- Buccigrossi V, Nicastro E, Guarino A. Functions of intestinal microflora in children. Curr. Opin. Gastroenterol. 2013;29:31–8. doi: 10.1097/MOG.0b013e32835a3500.
- Gordon JI. Honor Thy Gut Symbionts Redux. Science. 2012;336:1251–1253. doi: 10.1126/science.1224686.
- Wells JM, Rossi O, Meijerink M, van Baarlen P. Epithelial crosstalk at the microbiota-mucosal interface. Proc. Natl. Acad. Sci. USA. 2011;108(Suppl):4607–14. doi: 10.1073/pnas.1000092107.
- Stecher B, Hardt W-D. The role of microbiota in infectious disease. Trends Microbiol. 2008;16:107–14. doi: 10.1016/j.tim.2007.12.008.
- Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220–30. doi: 10.1038/nature11550.
- Yatsunenko T, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486:222–7.
- Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature. 2006;444:1022–1023. doi: 10.1038/4441022a.
- Willing BP, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139:1844–1854.e1. doi: 10.1053/j.gastro.2010.08.049.
- Chang JY, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 2008;197:435–8. doi: 10.1086/525047.
- Meng J, et al. Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-dependent manner. PLoS One. 2013;8:e54040. doi: 10.1371/journal.pone.0054040.
- Meng J, et al. Opioid Exacerbation of Gram-positive sepsis, induced by Gut Microbial Modulation, is Rescued by IL-17A Neutralization. Sci. Rep. 2015;5:10918. doi: 10.1038/srep10918.
- Mora AL, et al. Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am. J. Med. Sci. 2012;343:277–80. doi: 10.1097/MAJ.0b013e31822f42eb.
- Banerjee S, et al. Morphine induced exacerbation of sepsis is mediated by tempering endotoxin tolerance through modulation of miR-146a. Sci. Rep. 2013;3:1977. doi: 10.1038/srep01977.
- Banerjee S, et al. Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation. Mucosal Immunol. 2016;9:1418–1428. doi: 10.1038/mi.2016.9.
- Nicholson JK, et al. Host-Gut Microbiota Metabolic Interactions. Science. 2012;336:1262–1268. doi: 10.1126/science.1223813.
- Lawley TD, Walker AW. Intestinal colonization resistance. Immunology. 2013;138:1–11. doi: 10.1111/j.1365-2567.2012.03616.x.
- Buffie CG, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517:205–8. doi: 10.1038/nature13828.
- Venkatesh M, et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity. 2014;41:296–310. doi: 10.1016/j.immuni.2014.06.014.
- Heinken A, Thiele I. Systematic prediction of health-relevant human- microbial co-metabolism through a computational framework. Gut Microbes. 2015;6:120–130. doi: 10.1080/19490976.2015.1023494.
- Marcobal A, et al. A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice. ISME J. 2013;7:1933–43. doi: 10.1038/ismej.2013.89.
- Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. USA. 2009;106:14728–33. doi: 10.1073/pnas.0904489106.
- Claus SP, et al. Colonization-Induced Host-Gut Microbial Metabolic Interaction. MBio. 2011;2:1–8. doi: 10.1128/mBio.00271-10.
- Pacifici GM, Säwe J, Kager L, Rane A. Morphine glucuronidation in human fetal and adult liver. Eur. J. Clin. Pharmacol. 1982;22:553–558. doi: 10.1007/BF00609630.
- Frances B, Gout R, Monsarrat B, Cros J, Zajac JM. Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine. J. Pharmacol. Exp. Ther. 1992;262:25–31.
- Koster AS, Frankhuijzen-Sierevogel AC, Noordhoek J. Distribution of glucuronidation capacity (1-naphthol and morphine) along the rat intestine. Biochem. Pharmacol. 1985;34:3527–3532. doi: 10.1016/0006-2952(85)90728-2.
- Hawksworth G, Drasar BS, Hill MJ. Intestinal bacteria and the hydrolysis of glycosidic bonds. J. Med. Microbiol. 1971;4:451–459. doi: 10.1099/00222615-4-4-451.
- Walsh CT, Levine RR. Studies of the enterohepatic circulation of morphine in the rat. J. Pharmacol. Exp. Ther. 1975;195:303–10.
- Das S, Kelschenbach J, Charboneau R, Barke RA, Roy S. Morphine Withdrawal Stress Modulates Lipopolysaccharide-induced Interleukin 12p40 (IL-12p40) Expression by Activating Extracellular Signal-regulated Kinase 1/2, Which Is Further Potentiated by Glucocorticoids. J. Biol. Chem. 2011;286:29806–29817. doi: 10.1074/jbc.M111.271460.
- Babrowski T, et al. Pseudomonas aeruginosa virulence expression is directly activated by morphine and is capable of causing lethal gut-derived sepsis in mice during chronic morphine administration. Ann. Surg. 2012;255:386–93. doi: 10.1097/SLA.0b013e3182331870.
- Pham TAN, Lawley TD. Emerging insights on intestinal dysbiosis during bacterial infections. Curr. Opin. Microbiol. 2014;17:67–74. doi: 10.1016/j.mib.2013.12.002.
- McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane database Syst. Rev. 2013;8:CD006146.
- Sommer F, Bäckhed F. The gut microbiota — masters of host development and physiology. Nat. Rev. Microbiol. 2013;11:227–238. doi: 10.1038/nrmicro2974.
- Ursell LK, et al. The intestinal metabolome: an intersection between microbiota and host. Gastroenterology. 2014;146:1470–6. doi: 10.1053/j.gastro.2014.03.001.
- Turnbaugh PJ, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–4. doi: 10.1038/nature07540.
- Lötsch J, Geisslinger G. Morphine-6-glucuronide: an analgesic of the future? Clin. Pharmacokinet. 2001;40:485–99. doi: 10.2165/00003088-200140070-00001.
- Wang F, Roy S. Gut Homeostasis, Microbial Dysbiosis, and Opioids. Toxicol. Pathol. 2017;45:150–156. doi: 10.1177/0192623316679898.
- Ouellet DM, Pollack GM. Biliary excretion and enterohepatic recirculation of morphine-3-glucuronide in rats. Drug Metab. Dispos. 1995;23:478–84.
- Wang J, Barke RA, Charboneau R, Roy S. Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J. Immunol. 2005;174:426–34. doi: 10.4049/jimmunol.174.1.426.
- Degenhardt L, et al. Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies. Addiction. 2011;106:32–51. doi: 10.1111/j.1360-0443.2010.03140.x.
- Bäckhed F, et al. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe. 2012;12:611–22. doi: 10.1016/j.chom.2012.10.012.
- Fite A, et al. Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration. J. Clin. Microbiol. 2013;51:849–56. doi: 10.1128/JCM.02574-12.
- Greiner T, Bäckhed F. Effects of the gut microbiota on obesity and glucose homeostasis. Trends Endocrinol. Metab. 2011;22:117–123. doi: 10.1016/j.tem.2011.01.002.
- Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu. Rev. Immunol. 2012;30:759–95. doi: 10.1146/annurev-immunol-020711-074937.
- Keller R, et al. The Escherichia coli Envelope Stress Sensor CpxA Responds to Changes in Lipid Bilayer Properties. Biochemistry. 2015;54:3670–6. doi: 10.1021/acs.biochem.5b00242.
- Pellock, S. J. & Redinbo, M. R. Glucuronides in the Gut: Sugar-Driven Symbioses Between Microbe and Host. J. Biol. Chem. 10.1074/jbc.R116.767434 (2017).
- Stain-Texier F, Sandouk P, Scherrmann JM. Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat. Drug Metab. Dispos. 1998;26:383–7.
- Atmanene C, et al. Characterization of human and bovine phosphatidylethanolamine-binding protein (PEBP/RKIP) interactions with morphine and morphine-glucuronides determined by noncovalent mass spectrometry. Med. Sci. Monit. 2009;15:BR178–R187.
- Goumon Y, et al. Identification of morphine-6-glucuronide in chromaffin cell secretory granules. J. Biol. Chem. 2006;281:8082–8089. doi: 10.1074/jbc.M502298200.
- Bryant HU, Yoburn BC, Inturrisi CE, Bernton EW, Holaday JW. Morphine-induced immunomodulation is not related to serum morphine concentrations. Eur. J. Pharmacol. 1988;149:165–9. doi: 10.1016/0014-2999(88)90057-X.
- Ross GR, Gabra BH, Dewey WL, Akbarali HI. Morphine tolerance in the mouse ileum and colon. J. Immunol. 2008;327:561–572.
- Gohl DM, et al. Systematic improvement of amplicon marker gene methods for increased accuracy in microbiome studies. Nat. Biotechnol. 2016;34:942–9. doi: 10.1038/nbt.3601.
- Gohl, D. et al. An optimized protocol for high-throughput amplicon-based microbiome profiling. Protoc. Exch. 10.1038/protex.2016.030 (2016).
- Caporaso JG, et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods. 2010;7:335–6. doi: 10.1038/nmeth.f.303.
- Weingarden AR, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am. J. Physiol. Gastrointest. Liver Physiol. 2014;306:G310–9. doi: 10.1152/ajpgi.00282.2013.
- Lahti L, et al. Associations between the human intestinal microbiota, Lactobacillus rhamnosus GG and serum lipids indicated by integrated analysis of high-throughput profiling data. PeerJ. 2013;1:e32. doi: 10.7717/peerj.32.
- Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 2008;3:1101–1108. doi: 10.1038/nprot.2008.73.
Source: PubMed